Literature DB >> 21482488

Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals.

N A Al-Sweih1, M A Al-Hubail, V O Rotimi.   

Abstract

The development of resistance is a compelling reason for reviewing administration of antibiotics. Recently, most Acinetobacter infections are caused by multidrug-resistant (MDR) strains which have necessitated the use of tigecycline or colistin. This study was undertaken to determine the susceptibility of Acinetobacter spp. to these and other drugs. A total of 250 Acinetobacter isolates were collected from the 8 government hospitals over a period of 6 months. Susceptibility to 18 antibiotics, including tigecycline and colistin, was investigated by determining their minimum inhibitory concentrations using E test. Of the 250 isolates, 13.6% and 12% were resistant to tigecycline and colistin. A total of 25.2% and 37.2% were resistant to imipenem and meropenem, respectively. Of the 250 isolates 88.4% were MDR. This relatively high prevalence of tigecycline and colistin-resistant isolates indicates an emerging therapeutic problem which may severely compromise the treatment of MDR Acinetobacter spp. infections in Kuwait.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482488     DOI: 10.1179/joc.2011.23.1.13

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  22 in total

1.  Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections.

Authors:  Leticia V Bentancor; Jennifer M O'Malley; Cagla Bozkurt-Guzel; Gerald B Pier; Tomás Maira-Litrán
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

2.  In Vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii.

Authors:  Yan Bai; Bin Liu; Tianlin Wang; Yun Cai; Beibei Liang; Rui Wang; Youning Liu; Jin Wang
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

3.  Prevalence of antimicrobial resistance in Gram-negative clinical isolates from a major secondary hospital in Kuwait: a retrospective descriptive study.

Authors:  Walid Q Alali; Wadha AlFouzan; Rita Dhar
Journal:  Germs       Date:  2021-12-29

Review 4.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

5.  Molecular Surveillance of Multidrug-Resistant Acinetobacter baumannii.

Authors:  Aisha M AlAmri; Ameerah M AlQurayan; Tunny Sebastian; Amani M AlNimr
Journal:  Curr Microbiol       Date:  2019-12-12       Impact factor: 2.188

6.  Bacteremia caused by Acinetobacter junii at a medical center in Taiwan, 2000-2010.

Authors:  H-Y Tsai; A Cheng; C-Y Liu; Y-T Huang; Y-C Lee; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-06       Impact factor: 3.267

Review 7.  β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula.

Authors:  Hosam M Zowawi; Hanan H Balkhy; Timothy R Walsh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

8.  Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination.

Authors:  Yoshinori Sato; Tsuneyuki Ubagai; Shigeru Tansho-Nagakawa; Yusuke Yoshino; Yasuo Ono
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

9.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.

Authors:  Ignasi Roca; Paula Espinal; Xavier Vila-Farrés; Jordi Vila
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

10.  Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Authors:  Phillip J Bergen; Zackery P Bulman; Cornelia B Landersdorfer; Nicholas Smith; Justin R Lenhard; Jürgen B Bulitta; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Infect Dis Ther       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.